anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Use of FORADIL AEROLIZER as a single agent for the prevention of exercise-induced bronchospasm may be clinically indicated in patients who do not have persistent asthma. In patients with persistent asthma, use of FORADIL AEROLIZER for the prevention of exercise-induced bronchospasm may be clinically indicated, but the treatment of asthma should include a long-term asthma control medication, such as an inhaled corticosteroid. For adults and children 5 years of age or older, the usual dosage is the inhalation of the contents of one 12-mcg FORADIL capsule at least 15 minutes before exercise administered on an occasional as needed basis. When used intermittently as needed for prevention, protection may last up to 12 hours. 

Additional doses of FORADIL AEROLIZER should not be used for 12 hours after the administration of this drug. Regular, twice-daily dosing has not been studied in preventing EIB. Patients who are receiving FORADIL AEROLIZER twice daily for treatment of their asthma should not use additional doses for prevention of EIB and may require a short-acting bronchodilator.
Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
This research utilized single-cell RNA sequencing to map the immune cell landscape in sepsis, revealing 28 distinct cell clusters and categorizing them into nine major types. Delving into the monocyte/macrophage subclusters, 12 unique subclusters are identified and pathway enrichment analyses are conducted using KEGG and GO, discovering enriched pathways such as oxidative phosphorylation and antigen processing. Further GSVA and AUCell assessments show varied activation of interferon pathways, especially in subclusters 4 and 11. The clinical correlation analysis reveals genes significantly linked to survival outcomes. Additionally, cellular differentiation in these subclusters is explored. Building on these insights, the differential gene expression within these subclusters is specifically scrutinized, which reveal MYOF as a key gene with elevated expression levels in the survivor group. This finding is further supported by in-depth pathway enrichment analysis and the examination of cellular differentiation trajectories, where MYOF's role became evident in the context of immune response regulation and sepsis progression. Validating the role of the MYOF gene in sepsis, a dose-dependent response to LPS in THP-1 cells and C57 mice is observed. Finally, inter-cellular communications are analyzed, particularly focusing on the MYOF+Mono/Macro subcluster, which indicates a pivotal role in immune regulation and potential therapeutic targeting.
Soft tissue sarcomas represent 0.7% of all malignancies diagnosed in the United States. The peak incidence occurs in children and young adults with a second peak occurring in middle age, resulting in significant morbidity and mortality in young, productive individuals. Although limb preserving surgery and radiation therapy have improved the primary treatment of these tumors, the therapy of advanced, metastatic tumors is unsatisfactory. The purpose of this phase II study is to evaluate the efficacy of treatment with Alimta and gemcitabine given on day 1 of a 14 day cycle to patients with unresectable or metastatic soft tissue sarcomas. Gemcitabine is an established salvage therapy for soft tissue sarcomas in combination with docetaxel. Alimta is a multitargeted antifolate drug which inhibits several folate dependent enzymes required for cell proliferation. Alimta has shown efficacy in several solid tumor types both as a single agent and in combination with other agents. The combination of Alimta and gemcitabine is synergistic and is likely to have efficacy against soft tissue sarcomas. The primary objective of this study is to determine the response rate among patients with unresectable soft tissue sarcoma treated with this combination. Secondary endpoints will evaluate the median survival of this patient population, as well as time to objective tumor response, time to treatment failure and overall survival. The toxicities of this regimen in this population will also be analyzed. Given the desperate need for new agents to treat these patients, a phase II trial of this combination therapy should be pursued.
Phentermine will be started at 7.5 mg daily. Responders at Month 4 will continue the same treatment until Month 12.
Fast dissolving compacted formulation of ribavirin containing ribavirin free of its polymorphic forms and a pharmaceutically acceptable disintegrant wherein said formulation has a tap density of at least 0.6 g/ml, more than 80 % by weight of the ribavirin dissolves in water in 30 minutes and the disintegration time of the formulation is less than 10 minutes. The formulation is in the form for oral administration. A method for producing said formulation consists in admixing an antivirally effective amount of ribavirin ranging from 200 mg to 400 mg, an effective amount of pharmaceutically acceptable disintegrant ranging from 1.0 to 3.0 wt. % and an effective amount of at lest one filler ranging from 20 to 40 wt. %, compacting the prepared mixture at a compressing force in the range of 50 to 75 kN and admixing the compact with an effective amount of a lubricant ranging from 0.75 to 2.0 wt. %.
Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
BACKGROUND: Diabetic Nephropathy (DN) is characterized by albuminuria and a declining glomerular filtration rate (GFR) in diabetic patients. Plantago major (plantain) seed powder is traditionally used in these patients. Despite emerging and promising pre-clinical evidence, no clinical study investigated the potential efficacy of this intervention in patients with DN, which is the aim of this study.
METHODS: In a randomized clinical trial 60 DN patients were recruited from November 2022 to March 2023 and randomly assigned to the plantain group that received standard treatment (Losartan 25 mg twice a day) and plantain seeds' powder (10 gm sachet twice a day) plus sweet almond and the control group was received only standard treatment for 60 days. Proteinuria, as per 24-hour urinary protein, as well as fasting blood sugar (FBS), blood urea nitrogen (BUN), serum creatinine, serum potassium, and quality of life score were measured at baseline and after 60 days as study outcome measures.
RESULTS: Proteinuria was significantly decreased from 165.04 mg to 135.84 mg (p = 0.026) in the plantain group. The mean level of proteinuria was significantly lower in the plantain group (135.84 vs. 192.04, p = 0.039) compared to the control group after treatment. The plantain group showed more increase in quality of life score after treatment (33.89±9.67 vs 38.28±10.72, p = 0.041). Other outcomes showed no significant difference between the two study groups.
CONCLUSION: Adjuvant supplementation with plantain seeds powder may decrease proteinuria in patients with diabetic nephropathy. Further studies with larger sample sizes and longer duration are needed to confirm these results.
Previous studies have reported the high prevalence of hypertensive (HT) urgency. However, these studies have also reported low rates of serious complications, suggesting that rapid blood pressure (BP) reduction may be unnecessary. There are limited clinical data available on this topic in Asian populations. The investigators aimed to determine the basic characteristics, treatment methods, and outcomes in HT urgency patients, both in the emergency room (ER) and at a two-week follow-up.

This was a cohort study conducted at Srinagarind hospital, a tertiary-care level university hospital in Khon Kaen, Thailand. The data collection period was from January 2012 to June 2017. The Khon Kaen University Ethics Committee in Human Research approved the protocol. Patients aged 18 years or older who visited the ER with a diagnosis of HT urgency were consecutively enrolled in the study. Patients who were pregnant or lactating had secondary causes of HT, or had incomplete medical records were excluded from the study Office BP was measured using an upper arm cuff oscillometric BP device. The appropriate cuff size for each individual's arm circumference was used. Three BP readings were taken at 30-second intervals with the patient in a sitting position after five minutes of rest. The average of three BP measurements was used for analysis.

Baseline characteristic data were shown as the mean and standard deviation (SD) or percentage. An independent sample t-test was used to compare between groups for continuous variables including age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), time of treatment, and the number of medications being administered. A probability value \<0.05 was considered statistically significant. All statistical analyses were performed with SPSS for Mac version 20.0, registered to Khon Kaen University.
BACKGROUND: Accurate annotation of electrogram local activation time (LAT) is critical to the functional assessment of ventricular tachycardia (VT) substrate. Contemporary methods of annotation include: 1) earliest bipolar electrogram (LATearliest); 2) peak bipolar electrogram (LATpeak); 3) latest bipolar electrogram (LATlatest); and 4) steepest unipolar -dV/dt (LAT-dV/dt). However, no direct comparison of these methods has been performed in a large dataset, and it is unclear which provides the optimal functional analysis of the VT substrate.
OBJECTIVES: This study sought to investigate the optimal method of LAT annotation during VT substrate mapping.
METHODS: Patients with high-density VT substrate maps and a defined critical site for VT re-entry were included. All electrograms were annotated using 5 different methods: LATearliest, LATpeak, LATlatest, LAT-dV/dt, and the novel steepest unipolar -dV/dt using a dynamic window of interest (LATDWOI). Electrograms were also tagged as either late potentials and/or fractionated signals. Maps, utilizing each annotation method, were then compared in their ability to identify critical sites using deceleration zones.
RESULTS: Fifty cases were identified with 1,.813 ± 811 points per map. Using LATlatest, a deceleration zone was present at the critical site in 100% of cases. There was no significant difference with LATearliest (100%) or LATpeak (100%). However, this number decreased to 54% using LAT-dV/dt and 76% for LATDWOI. Using LAT-dV/dt, only 33% of late potentials were correctly annotated, with the larger far field signals often annotated preferentially.
CONCLUSIONS: Annotation with LAT-dV/dt and LATDWOI are suboptimal in VT substrate mapping. We propose that LATlatest should be the gold standard annotation method, as this allows identification of critical sites and is most suited to automation.
The goal of maintenance treatment with lamotrigine orally disintegrating tablets, USP is to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [see Indications and Usage (1.2)].

Patients taking lamotrigine orally disintegrating tablets, USP for more than 16 weeks should be periodically reassessed to determine the need for maintenance treatment.

Adults

The target dose of lamotrigine orally disintegrating tablets, USP is 200 mg/day (100 mg/day in patients taking valproate, which decreases the apparent clearance of lamotrigine, and 400 mg/day in patients not taking valproate and taking either carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitor lopinavir/ritonavir that increase the apparent clearance of lamotrigine). In the clinical trials, doses up to 400 mg/day as monotherapy were evaluated; however, no additional benefit was seen at 400 mg/day compared with 200 mg/day [see Clinical Studies (14.2)]. Accordingly, doses above 200 mg/day are not recommended. 

Treatment with lamotrigine orally disintegrating tablets, USP is introduced, based on concurrent medications, according to the regimen outlined in Table 5. If other psychotropic medications are withdrawn following stabilization, the dose of lamotrigine orally disintegrating tablets, USP should be adjusted. In patients discontinuing valproate, the dose of lamotrigine orally disintegrating tablets, USP should be doubled over a 2-week period in equal weekly increments (see Table 6). In patients discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation, the dose of lamotrigine orally disintegrating tablets, USP should remain constant for the first week and then should be decreased by half over a 2-week period in equal weekly decrements (see Table 6). The dose of lamotrigine orally disintegrating tablets, USP may then be further adjusted to the target dose (200 mg) as clinically indicated.

If other drugs are subsequently introduced, the dose of lamotrigine orally disintegrating tablets, USP may need to be adjusted. In particular, the introduction of valproate requires reduction in the dose of lamotrigine orally disintegrating tablets, USP [see Drug Interactions (7), Clinical Pharmacology (12.3)].

To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations of lamotrigine orally disintegrating tablets, USP should not be exceeded [see Boxed Warning]. 

Table 5. Escalation Regimen for Lamotrigine Orally Disintegrating Tablets, USP in Adults with Bipolar Disorder

Table 6. Dosage Adjustments to Lamotrigine Orally Disintegrating Tablets, USP in Adults with Bipolar Disorder following Discontinuation of Psychotropic Medications
Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
Participants in this group will receive brief pre-recorded DSMES videos, which include both educational and Social Cognitive Theory-based behavioral content. Participants will receive 1 DSMES video via text message each week for a total of 24 weeks with each video lasting about 5 minutes in duration. In addition, they will also receive brief phone calls from CHWs every 2 weeks during the 24 weeks video program. During these calls, CHWs will assess whether participants need assistance on social determinants of health (SDOH) barriers. If needed, CHWs will link participants to available services within the community. CHWs will also provide assistance on navigating the complex health care systems and serve as an advocate for patients during doctor visits if needed.
AIMS: Heart failure (HF) elicits a pro-inflammatory state, which is associated with impaired clinical outcomes, but no anti-inflammatory therapies have demonstrated a clinical benefit yet. Inflammatory pathways related with the interleukin-1 axis are overactivated during episodes of acute HF. Colchicine, an anti-inflammatory drug with proven benefits in acute pericarditis and ischaemic heart disease, may target this inflammatory response. This study aims to assess the efficacy of colchicine in acute HF patients.
METHODS: COLICA is a multicentre, randomized, double-blind, placebo-controlled trial enrolling 278 patients across 12 sites. Patients presenting with acute HF, clinical evidence of congestion requiring ≥40 mg of intravenous furosemide and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >900 pg/ml, are eligible for participation. Patients are enrolled irrespective of left ventricular ejection fraction, HF type (new-onset or not) and setting (hospital or outpatient clinic). Patients are randomized 1:1 within the first 24 h of presentation to either placebo or colchicine, with an initial loading dose of 2 mg followed by 0.5 mg every 12 h for 8 weeks (reduced dose if <70 kg, >75 years old, or glomerular filtration rate <50 ml/min/1.73 m2). The primary efficacy endpoint is the time-averaged proportional change in NT-proBNP concentrations from baseline to week 8. Key secondary and exploratory outcomes include symptoms, diuretic use, worsening HF episodes, related biomarkers of cardiac stress and inflammation, total and cardiovascular readmissions, mortality and safety events.
CONCLUSION: COLICA will be the first randomized trial testing the efficacy and safety of colchicine for acute HF.
X-ray contrast agents are provided in the form of tablets having a shaped core of a water-insoluble, powdery inorganic X-ray contrast substance and at least one binding agent, the core being coated with a layer of a basic foodstuff which is insoluble in water and does not swell or only swells slowly, and which is decomposed only in the presence of the corresponding enzymes.  The X-ray contrast substance may be bismuth silicate, barium silicate, silver iodide, barium sulphate or thorium oxide.  The binding agent may be starch, sugar, pectin, gum arabic.  The core may be isolated from the foodstuff layer by a soluble or easily decomposable layer, e.g. of sugar, pectin, milk sugar, dextrose, fruit sugar, mannite, water-soluble methyl cellulose, gum arabic, polyvinyl-pyrrolidone.  The foodstuff layer may be finally coated with a protective layer of sugar, milk sugar, dextrose, fruit sugar, pectin, starch sugar, &c.  The foodstuff may be (i) a fat melting above 37 DEG C, e.g. beef- or mutton-tallow, hardened peanut-, cottonseed-palm-, whale- or rape-oil, propylene glycol distearate, glyceryl esters of fatty acids with a carbon chain of 16-20 carbon atoms obtained by oxidizing paraffins, or (ii) a protein, e.g. egg or serum albumin, or serum globulin rendered water-insoluble by heat or treatment with, e.g. formaldehyde, glyoxal or tannin, or fibrinogen treated with thrombin, or muscle protein which may have been subjected to heat-treatment, or (iii) a carbohydrate especialy various starches which may be mixed with dextrine, tragacanth, agar agar, gum arabic &c. and, after application, heated to 100-140 DEG C.  The foodstuffs may contain preserving agents, and may be dyed for characterization.  Also the pills may have a shape characteristic of the particular foodstuff. Coating may be effected by dipping the pills in the foodstuffs in molten state or, dissolved or suspended in a liquid, or in a coating drum, or by spraying.  Fibrinogen and thrombin may be sprayed alternately.  One component may be applied in liquid form, and, another of the same foodstuff group, in powdered form.
Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
<P>PROBLEM TO BE SOLVED: To provide a functional composition for oral administration, effective for the restoration of abraded cartilage, the lessening of pain and the reduction of stress caused by arthralgia to assure a comfortable life with quiet and deep sleep, giving comprehensive satisfaction and common sensation, having quick action and takable as a food.  <P>SOLUTION: The functional composition for oral administration contains 0.01-100 pts. wt. of taurine and/or 0.01-100 pts. wt. of γ-aminobutyric acid per 100 pts. wt. of glucosamine or its edible salt. More preferably, the functional composition further contains 0.5-1,500 pts. wt. of at least one kind of component selected from mucopolysaccharide, mucopolysaccharide complex and mucopolysaccharide protein complex and 0.5-500 pts. wt. of a salicin-containing vegetable extract.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The invention describes an immunogen or immunogenic preparation derived from cells, cell membranes or proteins therefrom, that have been modified by treatment with a 2',3'-nucleoside or nucleotide dialdehyde crosslinking agent and by exposure to hydrostatic pressure. The pressure and crosslinker treatment of cells performed in accordance with the invention is termed 'PCL-modification'. Improved immunogenicity is obtained if the cells are treated with pressure at the same time that they are subjected to the protein crosslinking compounds. The cells suitable for PCL-modification in accordance with the invention and for use as immunogens may be tumor or cancer cells, transformed cells, virus-infected or microorganism-infected cells, e.g., bacteria, parasites, yeast, and the like. The PCL-modified tumor or infected cells are especially capable of inducing and eliciting a specific and potent immune response against the respective tumor cells, infected cells, or otherwise altered cells in both animals and human patients. Human peripheral blood mononuclear cells (PBMC) are sensitized and specifically stimulated to immunoreact against PCL-modified tumor or infected cells as determined by in vitro sensitization assays. Such assays, alone and in combination with PBMC cytokine analyses, serve as prognostic means to determine or identify those patients who will either respond or will not respond to PCL-immunotherapies and treatments, both in vitro and in vivo.
The invention belongs to the field of biochemistry and molecular immunology, and discloses a specific antigenic peptide of a polyclonal antibody aiming at ppGalNAc-T13, and its preparation method and use. The specific antigenic peptide is a polypeptide having an amino acid sequence shown in the SEQ ID NO: 2 or is a conservative variant polypeptide of the polypeptide. The degree of similarity between ppGalNAc-T13 and ppGalNAc-T1 reaches as high as 85%. The polyclonal antibody specifically aiming at ppGalNAc-T13 does not have a cross reaction with ppGalNAc-T1 and other members of a ppGalNAc-Ts family. In the invention, an antigen is obtained by a prokaryotic expression system and through a technical scheme that the antigen carries a glutathione S-transferase tag, products are purified easily. The preparation method provided by the invention is simple. A prepared antibody has strong immunogenicity.
This study was a randomized, open-label, single-dose, two-period, crossover study which included 34 healthy adult male and female subjects under fasting conditions. A single dose of experimental drug or comparator was administered in each of the two study periods (separated by a washout period of 1 week). Serial blood samples were collected up to 36 hours post-dose. Plasma drug concentrations were measured by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters, including maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve from dosing to the last measurable concentration (AUCt), were determined by non-compartmental analysis. The geometric mean ratios and associated 90% confidence intervals (CIs) of log-transformed Cmax and AUCt were calculated to evaluate pharmacokinetic equivalence.
Continuous with oral care as usual, either by themselves or nursing assisted (help with oral hygiene procedure) during the whole study period. Home care aides working with the control study participants deliver a toothbrush and fluoride toothpaste (\> 4000 ppm) (n:3) every third month during the study period.